CS MEDICA and RongShi strengthened the progress of their Joint Venture on its second Joint Fair at CPHI & PMEC in Guangzhou ,China 2023 (September 4-6), Asia’s premier pharma event.

CS MEDICA, a leading MedTech company specializing in Cannabis and Pain Management, is excited to provide an update of its Joint Venture, RongShi MEDICA (Ordos) Co., Ltd. (“RongShi MEDICA”, “JV” or “Joint Venture”) – the Joint Venture partnership between CS MEDICA (“CS MEDICA” or “the Company”) and Inner Mongolia Rong Shi Hi-Tech Co., Ltd (“RongShi”).

The Joint Venture has successfully participated in two prominent industry events:

• In June,RongShi MEDICA made its fair debut at CPHI, China (19-21 June 2023) in Shanghai. This inaugural appearance at the world’s nutraceutical event garnered the attention of approximately 15,000 industry experts from over 130 countries. The fair was a resounding success, resulting in valuable contacts and heightened awareness for the Joint Venture. Further CS MEDICA received inquiries from global and potential partners across the APAC region. Founders from both companies participated in the fair.
• CPHI & PMEC, China (4-6 September 2023) in Guangzhou, South China Station. Like the fair in June, this fair offers extensive business opportunities in the Chinese pharmaceutical market.  During the fair severable, valuable leads were secured and engaged with potential customers. Additionally, numerous new opportunities emerged, and exciting discussions are underway.  Founders from both companies participated in the fair.

Lone Henriksen, CEO at CS MEDICA and Jason, Managing Director, RongShi MEDICA in joint conversation with an potential customer.

Lone Henriksen, CEO at CS MEDICA and Board member at RongShi MEDICA, states, “The continued success of our Joint Venture emphasizes the persistent commitment of CS MEDICA and RongShi to drive the future of healthcare in China and beyond. We eagerly anticipate furthering our accomplishments, cultivating fresh partnerships, and maintaining our position as pioneers in pharmaceutical innovation.”

Jason, Managing Director, RongShi MEDICA, continues “We are thrilled to engage in productive interactions, meaningful discussions, and the establishment of strategic alliances at the current CPHI & PMEC China 2023 event. The engagement and will to win the Chinese market from CS MEDICA shows us that we collectively steer the course of healthcare’s future in China and across the vast Asian market.”

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating globally within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments with CBD for autoimmune and stress-related disorders under the trademark CANNASEN® or own-label options.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com, and LinkedIn.

Tags: